- Home
- RERE vs TLRY Comparison
RERE vs TLRY Comparison
Compare RERE & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- TLRY
- Stock Information
- Founded
- RERE 2011
- TLRY N/A
- Country
- RERE China
- TLRY Canada
- Employees
- RERE N/A
- TLRY N/A
- Industry
- RERE Other Specialty Stores
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- RERE Consumer Discretionary
- TLRY Health Care
- Exchange
- RERE Nasdaq
- TLRY Nasdaq
- Market Cap
- RERE 678.4M
- TLRY 637.2M
- IPO Year
- RERE 2021
- TLRY 2018
- Fundamental
- Price
- RERE $2.14
- TLRY $0.45
- Analyst Decision
- RERE
- TLRY Hold
- Analyst Count
- RERE 0
- TLRY 4
- Target Price
- RERE N/A
- TLRY $1.58
- AVG Volume (30 Days)
- RERE 1.0M
- TLRY 26.1M
- Earning Date
- RERE 05-19-2025
- TLRY 04-08-2025
- Dividend Yield
- RERE N/A
- TLRY N/A
- EPS Growth
- RERE N/A
- TLRY N/A
- EPS
- RERE N/A
- TLRY N/A
- Revenue
- RERE $2,237,042,920.00
- TLRY $826,656,000.00
- Revenue This Year
- RERE $29.57
- TLRY $11.80
- Revenue Next Year
- RERE $24.43
- TLRY $5.41
- P/E Ratio
- RERE N/A
- TLRY N/A
- Revenue Growth
- RERE 25.93
- TLRY 11.22
- 52 Week Low
- RERE $1.53
- TLRY $0.43
- 52 Week High
- RERE $3.70
- TLRY $2.52
- Technical
- Relative Strength Index (RSI)
- RERE 26.24
- TLRY 29.90
- Support Level
- RERE $2.12
- TLRY $0.46
- Resistance Level
- RERE $2.40
- TLRY $0.52
- Average True Range (ATR)
- RERE 0.21
- TLRY 0.05
- MACD
- RERE -0.06
- TLRY -0.01
- Stochastic Oscillator
- RERE 2.11
- TLRY 8.33
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.